^
    over2years
    Exact Sciences showcases breadth of early detection and treatment guidance portfolio with multiple data presentations at ASCO 2022 (Exact Sciences Press Release)
    "Exact Sciences Corp...announced new data supporting its cancer tests and treatment guidance tools will be showcased in nine poster presentations and five e-abstracts at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 3-7 in Chicago, Illinois...The analyses support use of Oncomap™ and Oncomap™ ExTra, comprehensive genomic profiling tests formerly known as the Oncotype Map™ Pan-Cancer Tissue and GEM ExTra® tests, respectively, to inform targeted therapy selection and clinical trial options for patients with advanced solid tumors."
    Clinical data
    |
    Oncomap™ ExTra test • Oncotype MAP™ Pan-Cancer Tissue Test
    over2years
    Updated Guidelines from the American Urological Association Include Genomic Assays, such as the Oncotype DX GPS Test, for the First Time in Localized Prostate Cancer Patients (PRNewswire)
    "Exact Sciences Corp...announced the American Urological Association (AUA) updated their guidelines to include genomic assays, such as the Oncotype DX Genomic Prostate Score® (GPS™) test, when treating men with localized prostate cancer. The 2022 guidelines now state that clinicians may selectively use tissue-based genomic biomarkers when added risk-stratification may alter clinical decision-making....This is the first in-person AUA meeting where Exact Sciences will feature its full Oncotype® portfolio of urologic genomic assays, including the Oncotype DX® GPS test for localized prostate cancer; the Oncotype MAP™ Pan-Cancer Tissue test for solid tumors, including advanced prostate cancer; and the Oncotype DX AR-V7 Nucleus Detect® test for metastatic castration-resistant prostate cancer."
    Clinical guideline
    |
    Oncotype DX AR-V7 Nucleus Detect® test • Oncotype DX Genomic Prostate Score® Assay • Oncotype MAP™ Pan-Cancer Tissue Test
    over2years
    BRAF mutation classes and co-occurring mutations in NSCLC. (ASCO 2022)
    For the first time we report the incidence of BRAF mutation classes and associated co-mutations in NSCLC. These associations may help to explain therapeutic outcomes. The impact of coexisting STK11 mutations in class II subclasses warrants further investigation.
    Tumor mutational burden • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • STK11 (Serine/threonine kinase 11) • NF1 (Neurofibromin 1) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase)
    |
    BRAF V600E • BRAF mutation • BRAF V600 • STK11 mutation
    |
    Oncotype MAP™ Pan-Cancer Tissue Test
    almost3years
    Age-associated mutations in RAS-mutated versus RAS-nonmutated metastatic colorectal cancer. (ASCO-GI 2022)
    "The Oncotype MAP Pan-Cancer Tissue test identified numerous genomic changes in mCRC samples. There appears to be an association between age group and RAS status for three mutated genes, SMAD4, ABCC1, and RICTOR. The clinical implication is unclear and warrants further investigation with outcomes data.Mt = mutated, Wt = wild type."
    KRAS (KRAS proto-oncogene GTPase) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability) • HRAS (Harvey rat sarcoma viral oncogene homolog) • SMAD4 (SMAD family member 4) • ABCC1 (ATP Binding Cassette Subfamily C Member 1) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2)
    |
    MSI-H/dMMR • RAS wild-type • SMAD4 mutation
    |
    Oncotype MAP™ Pan-Cancer Tissue Test
    almost3years
    Molecular profiling to identify potential therapeutic targets in hepatocellular carcinoma. (ASCO-GI 2022)
    "The Oncotype MAP Pan-Cancer Tissue test identified molecular variants that could be used to inform treatment decisions in 86% of HCC samples, including 16% to an approved HCC therapy. The Oncotype MAP test may be considered as another tool in the management of advanced HCC patients."
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • FAT1 (FAT atypical cadherin 1)
    |
    Oncotype MAP™ Pan-Cancer Tissue Test
    over3years
    [VIRTUAL] Exhibitor Seminar: Exact Sciences (Genomic Health, Inc.) - Oncotype MAP™ Pan-Cancer Tissue Test: Best Practices for Decalcifying Bone Samples in Preparation for Genomic Profiling (USCAP 2021)
    Dr. Routh is also a faculty member in the Department of Pathology at the University of Arizona.
    Pan tumor
    |
    Oncotype DX Breast Recurrence Score®Test • Oncotype MAP™ Pan-Cancer Tissue Test